Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Doximity

Doximity, Inc. develops an online healthcare resource and interactive platform. The Company cloud-based platform enables its members to collaborate with their colleagues, securely coordinate patient care, and conducts virtual patient visits. Doximity serves customers in the United States.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Doximity surpasses Q4 revenue expectations and eyes continued growth

Doximity's Q4 2023 performance exceeded expectations, showcasing strong financial metrics and strategic investments. The company's outlook for Q1 2024 indicates continued growth, with a focus on topline expansion and product innovation. While facing challenges in pricing strategies and competitive landscape, Doximity is well-positioned to capitalize on opportunities in the healthcare technology sector.

Doximity reports strong Q1 results but lowers 2024 guidance

Doximity delivered strong financial performance in Q1, but challenges in upsell close rates led to a downward revision in annual guidance. The company's focus on innovation, expansion, and shareholder value, along with a cautious outlook for the remainder of the year, presents a mixed picture of opportunities and challenges for investors.

Doximity reports strong Q3 earnings, eyes growth amid product challenges

Doximity's Q3 performance demonstrated resilience and growth potential despite challenges in meeting annual guidance due to product delays.
The company's focus on innovation, strong client relationships, and strategic investments position it well for future growth and market leadership.
With a commitment to R&D, expanding product offerings, and maintaining pricing discipline, Doximity aims to capitalize on opportunities and navigate challenges for sustained success.

Doximity surpasses Q4 revenue targets, poised for growth and innovation

Doximity's Q4 performance exceeded expectations, with robust revenue growth, strong margins, and strategic investments in new products and talent.
While facing challenges like flat growth in certain segments and pricing adjustments, the company is well-positioned to capitalize on opportunities in network expansion and technology innovation.
With a focus on enhancing user experience, driving engagement, and optimizing revenue streams, Doximity is poised for continued success and value creation for shareholders.
The company's financial health, innovative product offerings, and market positioning indicate a promising outlook for sustained growth and competitive advantage in the healthcare technology sector.

Doximity surpasses Q1 revenue expectations, faces upsell challenges

Doximity's Q1 performance was strong, but challenges in upsells prompted a staff reduction and revised guidance. The company is optimistic about long-term growth, leveraging new products and a self-serve ad platform for future success.

Doximity beats Q2 expectations, eyes growth amidst market uncertainties

Doximity's strong Q2 performance exceeded revenue and EBITDA guidance, driven by record physician engagement and new product success.
While facing market uncertainties and competition challenges, the company sees opportunities in pricing strategies and continued growth.
Investments in high-touch services, Telehealth, and video products are paying off, with a focus on enhancing client offerings.
Integration with IQVIA for real-time ROI analysis positions Doximity for future growth and client value creation.

Doximity beats Q3 revenue, eyes growth through AI products

Doximity's Q3 performance exceeded expectations with strong revenue and margin growth. The company faces challenges with elongated sales cycles but has opportunities for growth through AI products and new modules. Overall, Doximity's competitive position remains strong in the market.

Doximity exceeds Q4 revenue, eyes mid-teens growth post-COVID

Doximity's Q4 earnings call highlighted strong financial performance, customer satisfaction initiatives, and growth opportunities in digital marketing and new business segments. While facing challenges in growth slowdowns and market uncertainties, the company is leveraging strengths in optimized margins, visibility into revenue guidance, and customer commitment to drive future success.

Doximity excels in Q1 2025, driving growth through client value

Doximity's Q1 2025 performance reflects strong revenue growth, operational efficiency, and client value proposition.
The company's focus on innovation, customer engagement, and strategic insights positions it well for sustained growth.
Despite challenges, Doximity's proactive approach to industry dynamics and growth opportunities bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

This platform for medical professionals is worth a closer look.

1 Under-the-Radar Growth Stock to Buy in July

Teladoc

The market has become much more conservative in the last few months due to inflation & recession fears. The Pandemic accelerated the transition of Telehealth.

Pair Trade: Going Long Doximity And Short Teladoc

Growth stocks finished off an absolutely terrible first half of the year.

Why Doximity Stock Fell More Than 11% This Week

Datadog

MercadoLibre

Instead of stock splits, you might want to focus on these three stellar businesses.

Beyond Stock Splits: 3 Top Growth Stocks to Buy Now

Avantor Inc.

AVTR vs. DOCS: Which Stock Is the Better Value Option?

Doximity (DOCS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Doximity (DOCS) Surges 6.6%: Is This an Indication of Further Gains?

Intellia Therapeutics

Transmedics Group Inc

Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.

Up 1,000% in 5 Years? Here Are 3 Stocks That Can Run That High

Abbott Labs

These two businesses are stronger than ever, but their stock prices are at their lowest points in at least a year.

2 Top Healthcare Stocks Near 52-Week Lows to Buy

Doximity Inc. ( DOCS , Financial) appears at first glance to be a health care stock, but it's also a tech stock. In fact, Doximity operates in telehealth fielding education, promoting communication and improving access to care while lowering patient costs.

Doximity Inc.: A Healthy Value Stock

Cloud-based healthcare community platform Doximity (NASDAQ: DOCS) stock may be put in a bottom as its trades down (-35%) for the year.

Doximity Stock is an Interesting Healthcare Play

Adobe

Roku

Buying the right beaten-down stocks this summer could supercharge your portfolio for years to come.

3 Growth Stocks I'm Ready to Buy If the Market Crashes in June

Global-e Online Ltd

The market will inevitably bounce back, and these two stocks could help lead the recovery.

2 Growth Stocks to Buy Before the Market Rebounds

Coinbase

Carvana

Alphabet

GitLab

Hilton Worldwide Holdings

Tracking insider buying allows retail investors to take a look at how insiders view their company. This week, the list includes COIN and CVNA stocks.

6 Top Insider Buys of the Week

Now could be the time to buy shares of Doximity.

This High-Powered Growth Stock Just Beat Earnings and Is Trading Near Its 52-Week Low

Tech Stock Sell-Off Got You Scared? Here's a Better Buy.

The fifth article in our Broken Growth series focuses on a founder-led company. Doximity is a targeted social media platform with approximately 80% of all U.S. providers, including doctors, nurse practitioners and physician assistants.

Broken Growth Stocks: Doximity

Investors might have overreacted to an expected near-term revenue decline.

Why Doximity Stock Dropped Today

Weak forward guidance from Doximity is dragging DOCS stock down today. Shares briefly dipped below their IPO price.

Why Is Doximity (DOCS) Stock Down 15% Today?

Doximity Inc (NYSE: DOCS) shares are trading lower Wednesday after the company reported financial results and issued quarterly guidance below analyst estimates. Doximity said fiscal fourth-quarter revenue increased 40% year-over-year to $93.7 million, which beat the $90.11-million estimate,.

Why Doximity Stock Is Falling Today

Doximity, Inc. (NYSE:DOCS ) Q4 2022 Earnings Conference Call May 17, 2022 5:00 PM ET Company Participants Perry Gold - Head, Investor Relations Jeff Tangney - Co-Founder and Chief Executive Officer Nate Gross - Co-Founder and Chief Scientific Officer Anna Bryson - Chief Financial Officer Conference Call Participants Stephanie Davis - SVB Securities Ryan Daniels - William Blair Glen Santangelo - Jefferies Brian Peterson - Raymond James Matt Shea - Needham Cindy Motz - Goldman Sachs Richard Close - Canaccord Genuity Sandy Draper - Guggenheim Jessica Tassan - Piper Sandler Operator Ladies and gentlemen, thank you for standing by and welcome to Doximity's Fourth Quarter Fiscal 2022 Earnings Call. [Operator Instructions] Thank you.

Doximity, Inc. (DOCS) CEO Jeff Tangney on Q4 2022 Results - Earnings Call Transcript

Doximity Inc. shares plunged toward all-time lows in after-hours trading Tuesday, following an earnings report that projected an unexpected revenue decline in the current quarter.

Earnings Results: Doximity stock plummets after forecast, heads lower than IPO price for first time

Q4 total revenues of $93.7 million , up 40% year-over-year Q4 net income margin of 39% and adjusted EBITDA margin of 42% Fiscal Year 2022 total revenues of $343.5 million, up 66% year-over-year Fiscal year 2022 net income margin of 45% and adjusted EBITDA margin of 44% SAN FRANCISCO, May 17, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results for the fiscal 2022 fourth quarter and fiscal year ended March 31, 2022. "We're proud to now serve over 2 million US healthcare professionals, including over 80% of US physicians and over 50% of Physician Assistants and Nurse Practitioners," said Jeff Tangney, co-founder & CEO at Doximity.

Doximity Announces Fourth Quarter and Fiscal Year 2022 Financial Results

Doximity Inc. is scheduled to report earnings after Tuesday's close. Here's a closer look.

Earnings Preview: What To Expect From Doximity On Tuesday

Doximity's (DOCS) fiscal fourth-quarter results are likely to reflect continued strength in its telehealth platform.

Doximity (DOCS) to Report Q4 Earnings: What's in the Offing?

Axsome Therapeutics

10X Genomics

Here's why three Fool.com contributors love 10x Genomics, Axsome Therapeutics, and Doximity.

News for Doximity Stock (DOCS)